Fig.4
BTK inhibitors down-regulated CYLD phosphorylation and inhibited tumor growth in vivo. a, b CB17-SCID mice were injected subcostally with 5.0 × 106 OCI-ly10 cells or placebo control, tumor growth (a) and tumor volume (b) were assessed. The bars represent the mean ± S.D. from three independent experiments. **P < 0.01. c Non-GCB-DLBCL xenografted mice were treated with placebo or ibrutinib 12 mg/kg, tumor tissue lysates were blotted with the indicated antibodies to phospho-CYLD/CYLD and GAPDH